A composite drug delivery platform and its preparation method and application

By combining PCOF with TCA, a photosensitive skeleton is formed and the use of light to activate reactive oxygen production, the problem of single function of COFs drug delivery system and difficulty in releasing control is solved, precise treatment of periodontitis is achieved, and the amount of drug use and tolerance of the drug is reduced. Drug properties risk improves treatment efficiency and stability.

CN118718018BActive Publication Date: 2024-11-29JILIN UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411232353.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-29
Estimated Expiration
2044-09-04

AI Technical Summary

Technical Problem

The existing drug delivery system based on covalent organic framework materials (COFs) has a single function, difficult to control the release accuracy and rate, and is costly, making it difficult to achieve accurate and targeted drug delivery.

Method used

Using the preparation method of a compound drug-loading platform, by combining PCOF with TCA, a photosensitive skeleton is formed, and the production of reactive oxygen species is activated by light to achieve accurate and targeted release of drugs. Combined with chemotherapy and photodynamic therapy, the amount of drug use and drug resistance is reduced. risk.

Benefits of technology

It has achieved effective antibacterial effects on periodontitis, and accurately released drugs through light control, reducing the risk of drug use and drug resistance, and improving treatment efficiency and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118718018B_ABST
    Figure CN118718018B_ABST
Patent Text Reader

Abstract

The present invention is applicable to the technical field of drug carriers, and provides a composite drug delivery platform and a preparation method and application thereof. The present invention selects a columnar aromatic hydrocarbon-based covalent organic skeleton as a drug carrier, and a molecule that can respond to active oxygen to release an antibacterial active drug as a prodrug, and mixes and stirs the two to prepare a PCOF@TCA composite drug delivery platform. Under light irradiation, the photosensitive skeleton effectively produces exogenous active oxygen, thereby effectively inhibiting periodontal pathogens. It synergizes with the endogenous active oxygen present in the periodontal inflammation microenvironment and dental plaque biofilm, further increasing the level of active oxygen in the survival niche of pathogens. Excessive active oxygen rapidly triggers the decomposition of redox-sensitive prodrugs, promotes the rapid release of the effective drug ingredient cinnamaldehyde, and effectively alleviates periodontal infection. The present invention introduces a photosensitive skeleton as a medium to connect chemotherapy and photodynamic therapy, achieves an effective antibacterial effect on periodontitis, and accurately releases drugs by light control.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of drug carriers, and in particular relates to a composite drug-carrying platform and a preparation method and application thereof. Background Art

[0002] Drug delivery system refers to the system that assembles drugs with excipients, carriers or devices to form an effective drug delivery system. It aims to improve the bioavailability of drugs, reduce toxic side effects, and improve patient compliance. The designed and improved drug delivery system can improve the solubility, absorbability, distribution and metabolism of drugs, thereby improving the bioavailability of drugs. At the same time, it can reduce the contact between drugs and normal tissues and reduce drug toxicity. The most important thing is that it can improve the way of administration, reduce patient pain, and improve patient compliance. In recent years, the research and development of drug delivery systems has been rapid and has been widely used in the treatment of various diseases, including cancer, antibacterial, cardiovascular disease and diabetes. Its development trend and uses are mainly reflected in the following aspects: 1) Targeted drug delivery: selectively deliver drug molecules to the target site to improve the therapeutic effect of the drug. 2) Controlled release drug delivery: control the release rate of the drug, thereby prolonging the duration of drug action. Compared with rapid release of drugs, researchers generally choose sustained release. 3) Intelligent drug delivery: a system that releases drugs when stimulated by external stimuli. This type of drug delivery system can achieve both precision and targeting.

[0003] The combination of photocatalytic technology and drug delivery system is a new synergistic treatment strategy. This strategy uses light to induce photocatalysts to produce reactive oxygen species and other substances, which cooperate with drugs to kill tumors or bacteria. It has the advantages of improving treatment efficiency and reducing toxic side effects. The mechanism of synergistic treatment between drug delivery system and photocatalysis can be summarized as follows: 1) Light activates photosensitizers to produce intermediate substances such as reactive oxygen species to kill tumor cells or bacteria. 2) Reactive oxygen species produced by photocatalysis can enhance the killing effect of drugs and increase the apoptosis rate of tumor cells and bacteria. 3) Photocatalysis can reverse the drug resistance of tumor cells and bacteria and improve the sensitivity of drugs. Therefore, the development of a new drug delivery platform based on photocatalysis and controlled drug release for anti-tumor or antibacterial, especially sterilization through reactive oxygen species, is a promising research direction that can be transformed into practical results.

[0004] Covalent Organic Frameworks (COFs) are a type of two-dimensional or three-dimensional crystalline materials with a porous structure formed by organic units connected by covalent bonds. COFs have attracted widespread attention in drug loading platforms due to their high specific surface area, adjustable structure and function, good stability, etc., especially in the field of drug delivery, showing great application potential. However, most of the current COFs-based drug delivery systems have single functions (only as drug carriers), and the release accuracy and rate are difficult to control and the cost is high. Therefore, the purpose of the present invention is to develop a more economical and efficient COFs-based composite drug delivery platform to achieve precise and targeted drugs. Summary of the invention

[0005] The purpose of the present invention is to provide a composite drug delivery platform and a preparation method thereof, aiming to solve the problems raised in the above background technology.

[0006] To achieve the above object, the present invention provides the following technical solutions:

[0007] A method for preparing a composite drug-carrying platform comprises the following steps:

[0008] Step 1, synthesis of PCOF: 2-hydroxy-1,3,5-benzenetricarboxaldehyde, hydrazide-modified pillar aromatics, 2,5-dimethoxyterephthaloyl hydrazide and mesitylene are placed in a heat-resistant glass tube, and the mixture is ultrasonically treated for 10 min, followed by adding acetic acid and continuing the ultrasonic treatment for 5 min; after degassing in liquid nitrogen, the sealed tube is heated to room temperature and then placed in a 120°C oven for reaction for 3 days; after the reaction is completed, the wet powder is filtered and washed with tetrahydrofuran and dichloromethane to obtain a crude product; finally, the crude product is vacuum dried in an oven at 100°C for 12 h to obtain PCOF;

[0009] Step 2, synthesis of TCA: cinnamaldehyde and 3-mercaptopropionic acid were dissolved in ethyl acetate and stirred continuously in an ice bath for 15 min; trifluoroacetic acid was then added dropwise to the mixture and reacted in an ice bath for 30 min; the mixture was then transferred to room temperature and stirred in a vacuum overnight in the dark; after the reaction was completed, the reaction product was filtered and washed with n-hexane to obtain TCA;

[0010] Step 3, synthesis of PCOF@TCA: PCOF and TCA were weighed and stirred in an ethanol solution at 25°C overnight to obtain a composite drug loading platform.

[0011] Furthermore, the specific steps of step 1 are: 0.05 mmol 8.9 mg 2-hydroxy-1,3,5-benzenetricarboxaldehyde, 0.0375 mmol 32.5 mg hydrazide-modified pillar aromatics, 0.0375 mmol 9.5 mg 2,5-dimethoxyterephthaloyl hydrazide and 1 mL mesitylene are placed in a heat-resistant glass tube, and the mixture is ultrasonically treated for 10 min to obtain a uniform suspension, followed by adding 0.2 mL 6 M aqueous acetic acid and continuing ultrasonic treatment for 5 min; then degassing in liquid nitrogen 3 times, after degassing, the sealed tube is heated to room temperature, and then placed in a 120°C oven for reaction for 3 days; after the reaction is completed, it is filtered and washed with tetrahydrofuran and dichloromethane to obtain a wet powder to obtain a crude product; finally, the crude product is vacuum dried in an oven at 100°C for 12 h to obtain PCOF as a dark yellow powder.

[0012] Furthermore, the specific steps of step 2 are: dissolving 24.6 mmol 3.25g cinnamaldehyde and 53.9 mmol 5.72 g 3-mercaptopropionic acid in 15 mL of ethyl acetate and stirring continuously in an ice bath for 15 min; then adding trifluoroacetic acid dropwise to the mixture and reacting in an ice bath for 30 min; then transferring the mixture to room temperature and stirring in vacuum in the dark overnight; after the reaction is completed, filtering the reaction product and washing with n-hexane to obtain TCA as a white solid.

[0013] Furthermore, in step 3, PCOF and TCA are weighed according to a mass ratio of 1:3.

[0014] A composite drug-carrying platform prepared according to the above-mentioned preparation method.

[0015] An application of the composite drug-carrying platform described above in the preparation of drugs for treating periodontitis.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] The present invention can achieve effective antibacterial effect on periodontitis by introducing a photosensitive skeleton as a medium connecting chemotherapy and photodynamic therapy, and can accurately release drugs by light control, thereby reducing the amount of drugs used and the risk of drug resistance in patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 Diagram of the construction strategy of P-COF@TCA.

[0019] Figure 2 Schematic diagram of the sterilization mode of PCOF@TCA.

[0020] Figure 3In the figure, (a) is a schematic diagram of the bactericidal process of TCA oxidative cleavage to CA; (b) is the H NMR spectrum of CA, TCA and TCA cleavage process.

[0021] Figure 4 is the electron paramagnetic resonance spectrum of the active oxygen generated by PCOF; wherein (a) is TEMP- 1 O2; (b) DMPO-O2 •– .

[0022] Figure 5 CA release curve of PCOF@TCA under light conditions.

[0023] Figure 6 The antibacterial graph of PCOF@TCA.

[0024] Figure 7 In the figure, (a) is the UV-visible absorption spectra of TCA, PCOF and PCOF@TCA; (b) is the thermogravimetric curves of TCA, PCOF and PCOF@TCA; (c) is the specific N2 adsorption-desorption curves and specific surface areas of PCOF and PCOF@TCA; (d) is the visual element map of PCOF@TCA obtained by EDS measurement, including C, O, N and S; (e) is the transmission electron microscope image of PCOF@TCA.

[0025] Figure 8 Actual antibacterial image of PCOF@TCA in mouse gingiva. DETAILED DESCRIPTION

[0026] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0027] The specific implementation of the present invention is described in detail below in conjunction with specific embodiments.

[0028] An embodiment of the present invention provides a method for preparing a composite drug loading platform, comprising the following steps:

[0029] Step 1. Synthesis of PCOF: 2-Hydroxy-1,3,5-benzenetricarboxaldehyde (0.05 mmol, 8.9 mg), hydrazide-modified pillararene (0.0375 mmol, 32.5 mg), 2,5-dimethoxyterephthaloylhydrazide (0.0375 mmol, 9.5 mg) and mesitylene (1 mL) were placed in a heat-resistant glass tube. The mixture was sonicated for 10 min to obtain a uniform suspension, and then acetic acid (6 M aqueous solution, 0.2 mL) was immediately added and sonication was continued for 5 min. The tube was degassed in liquid nitrogen three times. The sealed tube was warmed to room temperature and then placed in an oven at 120 °C for 3 days. After filtration, the resulting wet powder was washed with tetrahydrofuran and dichloromethane to obtain a crude product. The material was further dried in a 100 °C oven under vacuum for 12 h to obtain PCOF as a dark yellow powder (24.5 mg, yield: 51%).

[0030] Step 2, synthesis of TCA: Cinnamaldehyde (24.6 mmol, 3.25 g) and 3-mercaptopropionic acid (53.9 mmol, 5.72 g) were dissolved in 15 mL of ethyl acetate and stirred continuously in an ice bath for 15 min. Subsequently, trifluoroacetic acid was added dropwise to the mixture. After reacting in an ice bath for 30 min, the mixture was transferred to room temperature and stirred overnight in a vacuum in the dark. Then, the reaction product was filtered and washed with n-hexane to finally obtain TCA as a white solid.

[0031] Step 3, synthesis of PCOF@TCA: PCOF and TCA were weighed in a mass ratio of 1:3 and stirred in an ethanol solution at 25°C overnight to obtain a PCOF@TCA composite drug delivery platform.

[0032] In the embodiment of the present invention, the present invention selects pillararomatic COFs (Pillararene-Embedded Covalent Organic Framework, PCOFs) as drug carriers, and molecules that can release antibacterial active drugs in response to active oxygen as prodrugs (such as Figure 1 As shown in the figure, taking the compound thioacetal (TCA) as an example, it can generate cinnamaldehyde (CA) under the stimulation of active oxygen. The two are mixed and stirred to prepare the PCOF@TCA composite drug delivery platform. The antibacterial active molecule CA released by PCOF@TCA is combined with the active oxygen generated by the system to achieve multiple bactericidal methods of chemotherapy and photodynamic therapy.

[0033] Bactericidal mode and mechanism of the composite drug delivery platform: Under light irradiation, the photosensitive skeleton PCOF effectively produces exogenous reactive oxygen species (Exogenous ROS), mainly including singlet oxygen ( 1O2) and superoxide radical anion (O2 •– ), thereby effectively inhibiting periodontal pathogens. In addition, the composite drug delivery platform synergizes with endogenous reactive oxygen species (Endogenous ROS) present in the periodontal inflammation microenvironment and dental plaque biofilm, further increasing the level of reactive oxygen species in the pathogen survival niche. Excessive reactive oxygen species rapidly trigger the decomposition of redox-sensitive prodrugs, promote the rapid release of CA, and effectively alleviate periodontal infection. The reactive oxygen responsive composite drug delivery platform prepared by the present invention realizes the rapid response of reactive oxygen species in the specific environment of periodontal inflammation, promotes the precise release of drugs, realizes the dual synergistic treatment of photodynamic therapy and antibacterial prodrugs, and effectively alleviates periodontal inflammation ( Figure 2 ).

[0034] In the composite drug delivery platform, the photosensitive skeleton PCOF will produce reactive oxygen species under light excitation, mainly including 1 O2 and O2 •– ( Figure 4 ), to achieve photodynamic therapy.

[0035] In addition, the present invention can select suitable inert groups and protect molecules with good bactericidal efficacy, including but not limited to cinnamaldehyde and mercaptopropionic acid. Under certain specific stimuli, such as light, heat energy and magnetism, the prodrug is cleaved and converted into active drug molecules ( Figure 3 In the present invention, the hydrogen at the aldehyde group of CA is used as a reference. Under the catalysis of active oxygen, a typical aldehyde group signal appears in the nuclear magnetic hydrogen spectrum of TCA, indicating that TCA is oxidatively cleaved into CA ( Figure 3 (b)

[0036] In practical applications, the prodrug molecules will be catalytically converted into effective antibacterial active molecules under the dual effects of reactive oxygen species generated by the photosensitive skeleton and endogenous reactive oxygen species of bacteria, and released through the porous platform of the photosensitive skeleton. The release curve of the composite drug-loading platform is shown in Figure 2. Figure 5 As shown in the figure, the drug release rate of the composite drug loading platform still has an upward trend after 48 h, showing the sustained release characteristics of the composite drug.

[0037] Example 1. Physicochemical properties and morphology of PCOF@TCA;

[0038] In order to verify that PCOF can successfully load the prodrug molecule TCA into the interior, a series of characterizations were performed. From the solid UV image of PCOF@TCA, it can be seen that ( Figure 7 In figure a), TCA molecules themselves have no absorption in the visible light region, while PCOF@TCA has an absorption range of 200-500 nm, which can reduce the damage of light sources to tissues. Thermogravimetric analysis of PCOF@TCA, PCOF, and TCA showed that the thermal stability of PCOF@TCA after loading was weakened, which further indicated the successful loading of TCA ( Figure 7 In addition, the difference in specific surface area between PCOF and PCOF@TCA is also due to the reduction in porosity caused by the successful filling of TCA ( Figure 7 (c). Figure 7 Figures d and e are the scanning electron microscope images and transmission electron microscope images of PCOF@TCA, respectively. The elemental analysis obtained from the scanning electron microscope image shows that the S element from TCA is evenly distributed in PCOF@TCA. At the same time, the regular black spheres in the transmission electron microscope image of PCOF@TCA also prove that TCA is loaded into PCOF in the form of clusters.

[0039] Example 2, antibacterial effect of PCOF@TCA;

[0040] In order to verify the actual antibacterial effect of PCOF@TCA, antibacterial experiments were conducted against Porphyromonas gingivalis and Fusobacterium nucleatum. A certain concentration of bacteria was inoculated on the surface of the culture medium, and different external stimuli were screened and applied one by one. Several different conditions were designed to evaluate the effects of different external stimuli on the antibacterial effect: (1) only using light and PCOF; (2) only using the PCOF@TCA composite drug delivery platform for antibacterial; (3) only using the PCOF@TCA drug delivery platform under blue light irradiation; (4) using the PCOF@TCA drug delivery platform and endogenous H2O2; (5) using the PCOF@TCA drug delivery platform and endogenous H2O2 under light. The experimental results show that under condition (5), that is, under the combined action of the PCOF@TCA composite drug delivery platform and endogenous H2O2 under light, the growth of the bacterial colony was severely inhibited ( Figure 6 ).

[0041] Example 3: Antibacterial effect of PCOF@TCA on mice;

[0042] In order to verify the antibacterial effect of PCOF@TCA, especially the therapeutic effect on the mouse model, an experiment was conducted. After light treatment with PCOF@TCA, the redness and swelling of the mouse gums disappeared, and the oral mucosa healed well. The recovery effects of other control groups including Periodontitis, Minocycline, pcof+l (PCOF+light), PCOF@TCA (composite drug delivery platform), and PCOF@TCA+l (composite drug delivery platform+light) all showed weak healing effects ( Figure 8 ).

[0043] In summary, the present invention can achieve an effective antibacterial effect on periodontitis by introducing a photosensitive skeleton as a medium connecting chemotherapy and photodynamic therapy, and can accurately release drugs by light control, thereby reducing the amount of drugs used and the risk of drug resistance in patients.

[0044] The above are only preferred embodiments of the present invention. It should be pointed out that, for those skilled in the art, several modifications and improvements can be made without departing from the concept of the present invention. These should also be regarded as the protection scope of the present invention. These will not affect the effect of the implementation of the present invention and the practicality of the patent.

Claims

1. A method for preparing a composite drug delivery platform, It is characterized in that The following steps are involved: Step 1, synthesis of PCOF: 2-hydroxy-1,3,5-benzenetricarboxaldehyde, hydrazide-modified pillar aromatics, 2,5-dimethoxyterephthaloyl hydrazide and mesitylene are placed in a heat-resistant glass tube, and the mixture is ultrasonically treated for 10 min, followed by adding acetic acid and continuing the ultrasonic treatment for 5 min; after degassing in liquid nitrogen, the sealed tube is heated to room temperature and then placed in a 120°C oven for reaction for 3 days; after the reaction is completed, the wet powder is filtered and washed with tetrahydrofuran and dichloromethane to obtain a crude product; finally, the crude product is vacuum dried in an oven at 100°C for 12 h to obtain PCOF; Step 2, synthesis of TCA: cinnamaldehyde and 3-mercaptopropionic acid were dissolved in ethyl acetate and stirred continuously in an ice bath for 15 minutes; trifluoroacetic acid was then added dropwise to the mixture and reacted in an ice bath for 30 minutes; the mixture was then transferred to room temperature and stirred in a vacuum overnight in the dark; after the reaction was completed, the reaction product was filtered and washed with n-hexane to obtain TCA; Step 3, synthesis of PCOF@TCA: PCOF and TCA were weighed and stirred in an ethanol solution at 25°C overnight to obtain a composite drug loading platform.

2. The method for preparing the composite drug loading platform according to claim 1, It is characterized in that The specific steps of step 1 are: 0.05 mmol 8.9 mg 2-hydroxy-1,3,5-benzenetricarboxaldehyde, 0.0375 mmol 32.5 mg hydrazide-modified pillar aromatics, 0.0375 mmol 9.5 mg 2,5-dimethoxyterephthaloyl hydrazide and 1 mL mesitylene are placed in a heat-resistant glass tube, and the mixture is ultrasonically treated for 10 min to obtain a uniform suspension, followed by adding 0.2 mL 6 M aqueous acetic acid and continuing ultrasonic treatment for 5 min; then degassing in liquid nitrogen for 3 times, after degassing, the sealed tube is heated to room temperature, and then placed in a 120° C. oven for reaction for 3 days; after the reaction is completed, the mixture is filtered and washed with tetrahydrofuran and dichloromethane to obtain a wet powder to obtain a crude product; finally, the crude product is vacuum dried in an oven at 100° C. for 12 h to obtain PCOF as a dark yellow powder.

3. The method for preparing the composite drug loading platform according to claim 1, It is characterized in that The specific steps of step 2 are: dissolving 24.6 mmol 3.25 g cinnamaldehyde and 53.9 mmol 5.72 g 3-mercaptopropionic acid in 15 mL of ethyl acetate and stirring continuously in an ice bath for 15 min; then adding trifluoroacetic acid dropwise to the mixture and reacting in an ice bath for 30 min; then transferring the mixture to room temperature and stirring in vacuum in the dark overnight; after the reaction is completed, filtering the reaction product and washing it with n-hexane to obtain TCA as a white solid.

4. The method for preparing the composite drug loading platform according to claim 1, It is characterized in that In the step 3, PCOF and TCA are weighed according to a mass ratio of 1:

3.

5. A composite drug loading platform prepared according to the preparation method according to any one of claims 1-4.

6. Use of the composite drug loading platform according to claim 5 in preparing drugs for treating periodontitis.

Citation Information

Patent Citations

  • Covalent organic framework material with photodynamic therapy effects and preparation method thereof

    CN110511391A

  • Preparation method and application of porous carbon supported nickel material

    CN113522292A